SCHEMBL7208525

SCHEMBL7208525

c1ccc(Nc2cc(-c3cscc3Sc3ccccc3)[nH]n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
GAA P10253 2/20 0.46
MAPT P10636 2/20 0.46
MEN1 O00255 1/20 0.46
TP53 P04637 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CHEK1 O14757 1/20 0.45
TNIK Q9UKE5 3/20 0.39
CDK2 P24941 5/20 0.36
CDK1 P06493 3/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
STAT1 P42224 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
FLT3 P36888 4/20 0.36
AURKA O14965 2/20 0.36
SRC P12931 1/20 0.36
GSK3B P49841 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7208335 0.80 ALDH1A1 (0.49) ALDH1A1GAAMAPTMEN1TP53
SCHEMBL7636488 0.75 CHEK1 (0.44) ALDH1A1GAAMAPTMEN1TP53
SCHEMBL18434151 0.71 CHEK1 (0.67) ALDH1A1GAAMAPTMEN1TP53
SCHEMBL3602280 0.71 MAPT (0.58) ALDH1A1GAAMAPTMEN1TP53
SCHEMBL7544095 0.67 FLT3 (0.64) ALDH1A1GAAMAPTMEN1TP53
SCHEMBL7204068 0.67 TNIK (0.62) ALDH1A1GAAMAPTMEN1TP53
SCHEMBL6242534 0.65 CDK2 (0.65) ALDH1A1GAAMAPTMEN1TP53
SCHEMBL30713745 0.64 ALDH1A1 (1.00) ALDH1A1GAAMAPTMEN1TP53
SCHEMBL21262430 0.63 CDK2 (0.67) ALDH1A1GAAMAPTMEN1TP53
SCHEMBL21262705 0.63 TNIK (0.66) ALDH1A1GAAMAPTMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1274706-A1 PYRAZOLES FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2003-01-15 EP disclosed
US-6462069-B2 KINASE INHIBITORS; ANTICANCER AGENTS AGOURON PHARMACEUTICALS, INC. 2002-10-08 US disclosed
WO-2001079198-A9 PYRAZOLES FOR INHIBITING PROTEIN KINASE AGOURON PHARMA (US) 2002-05-16 WO disclosed
US-20020006952-A1 Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases LIGHPOINTE COMMUNICATION, INC. 2002-01-17 US disclosed
WO-2001079198-A1 PYRAZOLES FOR INHIBITING PROTEIN KINASE AGOURON PHARMACEUTICALS, INC. (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006952-A1 Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases CDK3, CCNK, CDK1 ALDH1A1 3414/4885GAA 2707/4885MAPT 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.